BAALC

• About this biomarker
• Introduction to our products
• Why choose our products
• Main product for BAALC
• Associated product
• Related publications

The human gene BAALC (Brain And Acute Leukemia, Cytoplasmic) was identified by comparison of expression levels between blasts from AML with trisomy 8 and cytogenetically normal AML [Tanner SM et al. PNAS. 2001].

Recent studies have shown that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML patients with normal karyotype [Baldus CD et al. JCO. 2006, Bienz M et al. Clin Cancer Res. 2005, Langer C. et al., Blood. 2008, Santamaria C et al. Ann Hematol. 2010] but also that high BAALC expression in conjunction with FLT3 mutation status successfully identifies high-risk patients within the heterogenous group of cytogenetically normal AML patients [Baldus CD et al. JCO. 2006].

High BAALC expression is established as one of the most important independent risk factors associated with resistant disease, a high cumulative incidence of relapse, and reduced survival [Bienz M et al. Clin Cancer Res. 2005, Langer C. et al., Blood. 2008, Santamaria C et al. Ann Hematol. 2010].

BAALC ProfileQuant® kit use RQ-PCR technology to quantify BAALC gene expression relative to ABL control gene.

ProfileQuant® technology gives highly reproducible, calibrated and normalized RQ-PCR results.

Why choose BAALC ProfileQuant® kit ?

• Calibrated and sensitive quantification of BAALC gene expression, normalized with ABL control gene expression (results in NCN)
• Product manufactured under ISO 13485 certification ensuring optimal quality control and full traceability

BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia.
PNAS 2001
Authors:Tanner SM et al.

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications .
J Clin Oncol. 2006
Authors: Baldus CD et al.

Risk assessment in patients with Acute Myeloid Leukemia and a normal karyotype.
Clin Cancer Res. 2005
Authors: Bienz M et al.

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Blood. 2008
Authors: Langer C et al.

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Ann Hematol. 2010
Authors: Santamaria C et al.